Wednesday , March 29 2017
Home / Business News

Business News

Bristol-Myers Collaborates with Parker Institute and CRI for Immuno-Oncology Research

NEW YORK & SAN FRANCISCO–(BUSINESS WIRE)–The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely …

Read More »

Regeneron, UK Biobank and GSK Enter Gene Sequencing Initiative

TARRYTOWN, N.Y., March 22, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource. The initiative will enable researchers to gain …

Read More »

BioLineRx Acquires Cancer Immunotherapeutics Company Agalimmune

Tel Aviv, Israel – March 23, 2017 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has acquired Agalimmune Ltd., a private UK-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of which …

Read More »

Two Prime Therapeutics Studies Examine Diabetes Costs, How Appropriate Preventive Care Can Improve Outcomes

ST. PAUL, Minn.–(BUSINESS WIRE)–Two new studies find commercially insured members with diabetes had 2.5 times higher medical and pharmacy spending than members without diabetes matched by age, sex, state of residence and insurer. But those taking a cholesterol-lowering statin for primary prevention of heart disease – a common complication of …

Read More »

Pierre Fabre and H-Immune Partner on Immuno-Oncology Therapeutics

CASTRES and PARIS, France March 21, 2017 – Pierre Fabre, the second largest privately held pharmaceutical company in France, and H-Immune SAS, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, today announced that they have entered into a strategic research partnership which …

Read More »

X-Chem and Astellas Pharma Enter Strategic Collaboration Across Multiple Therapeutic Areas

WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. (Astellas). The collaboration will enable the discovery of novel lead compounds for complex …

Read More »

Bristol-Myers and CytomX Expand Collaboration to Discover Probody Therapeutics for Treatment of Cancer and Other Diseases

  NEW YORK & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today announced an expansion of their 2014 strategic collaboration to discover novel therapies that will include up to eight additional targets …

Read More »

PTC Therapeutics Acquires Marathon Pharma’s DMD Drug Emflaza for $140 Million

SOUTH PLAINFIELD, N.J., March 16, 2017 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza™ (deflazacort). Emflaza is the first treatment approved in the United States for all Duchenne muscular dystrophy (DMD) patients …

Read More »

Allergan and Editas Announce CRISPR-Based Research and Development Deal for Rare Eye Diseases

DUBLIN and CAMBRIDGE, Mass., March 14, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development alliance …

Read More »

Vertex Acquires Cystic Fibrosis Candidate from Concert Pharmaceuticals in Potential $250 Million Deal

BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE). CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination …

Read More »